Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Advancements and Perspectives in the Bioprosthetic Heart Valve: A Comprehensive Review on Biomaterial Processing and Emerging Polymeric Materials

Li H., Li S., Lei Y., Sun M., Wu C., Wang X.

Narrative Review on Systemic / IV, published in J Am Heart Assoc (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Am Heart Assoc (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40767293
PMCID
PMC12533660
DOI
10.1161/jaha.125.043061
Citations
1

Abstract (original English)

Heart valve disease contributes to cardiovascular disease-associated death. Bioprosthetic heart valves have emerged as a preferred option for heart valve replacement due to their superior hemodynamic performance and reduced need for lifelong anticoagulation. However, their long-term durability is compromised by calcification, immunogenicity, and structural degeneration, primarily due to glutaraldehyde fixation and residual xenogeneic antigens. This review highlights recent advances in biomaterial optimization, with an emphasis on decellularization and cross-linking strategies aimed at improving the mechanical stability and biocompatibility of bioprosthetic heart valves. The effectiveness and limitations of various decellularization agents, including nonionic, ionic, and amphoteric detergents, are critically evaluated, alongside novel cross-linking reagents such as ribose, genipin, and polyphenols. Furthermore, the development of polymeric heart valves and nanocomposite materials is also explored as a means to address the limitations of conventional mechanical and bioprosthetic valves. Emerging strategies involving gene-editing technologies, stem cell therapies, and tissue engineering hold considerable promise for the development of next-generation, patient-specific, and immunotolerant heart valve prostheses. Collectively, these innovations are driving a paradigm shift toward lo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansHeart Valve DiseasesPolymersBiocompatible MaterialsHeart Valve Prosthesis ImplantationTissue EngineeringProsthesis DesignBioprosthesisHeart Valve Prosthesis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research